A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL) Clinical Trial

Official title: An Open-label, Multicenter,Randomized Phase 2 Trial to Compare the Efficacy and Safety of Ibrutinib Versus Lenalidomide in Combination With MRE(Methotrexate,Rituximab,Etoposide)-Chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Status Recruiting

Clinical Trial Summary

This is a open-label，multicenter, randomised, three-arm, phase II efficacy and safety study of ibrutinib in combination with MRE(methotrexate,rituximab,etoposide)-chemotherapy versus lenalidomide in combination with MRE-chemotherapy given to adult patients who have recurrent/refractory primary central nervous system lymphoma (PCNSL)

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Lymphoma
• Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL)

• NCT number: NCT04129710
• Study type: Interventional
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: Xiaohong Zhang
• Phone: +8657189713673
• Email: zeyyxy@163.com
• Status: Recruiting
• Phase: Phase 2
• Start date: January 1, 2020
• Completion date: December 31, 2025